Skip to main content

Table 3 Comparing clinical and laboratory data of the patients at diagnosis (first assessment) and after 3 years (second assessment)

From: COL1A1 polymorphism and neurological complications in pediatric acute lymphoblastic leukemia patients and their associations with altered bone mineral density

  Acute lymphoblastic leukemia patients p value
First assessment Second assessment
BMI percentile 84th (70th–90th) 86th (75th–91th) 0.1
Neurological complications seizures (4%), peripheral neuropathy (10%), lumbosacral radiculopathy (10%)
Fracture detection 7 (7%)*
BMDLS − 1.9 ± 0.44 − 2.654 ± 0.11* 0.01*
Parathormon (ng/l) 45 (10–56) 49 (12–60) 0.8
Total calcium (mg/dl) 9 ± 0.9 10.8 ± 0.20 0.2
Vitamin D (nmol/l) 44 (6–59) 40(12–55) 0.2
Osteocalcin (ng/ml) 18 (9–23) 13 (–20)* 0.01*
Alkaline phosphatase (U/L) 99 (60–135)* 75 (4–88)* 0.04*
  1. BMDLS bone mineral density of lumbar spine, PTH parathormon, OC osteocalcin, ALP alkaline phosphatase
  2. *Significant